Tag: Precision oncology for gynecologic cancers

Home / Precision oncology for gynecologic cancers

Categories

Durvalumab with chemotherapy is approved by the USFDA for mismatch repair deficient primary advanced or recurrent endometrial cancer

  June 2024: The Food and Drug Administration has granted approval for the use of durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with carboplatin and paclitaxel, followed by singl...
precision-oncology-for-gynecologic-cancers

Scan the code